Human papillomavirus (9-valent) vaccine is under clinical development by Xiamen Innovax Biotech and currently in Phase II for Human Papillomavirus Infections.

Zigakibart is under clinical development by Novartis and currently in Phase III for IgA Nephropathy (Berger's Disease).

Danazol is under clinical development by Viramal and currently in Phase II for Endometriosis. According to GlobalData, Phase II drugs for Endometriosis have a 30% phase transition success rate (PTSR) ...

Novaferon is under clinical development by Genova Biotech and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

TQB-2223 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Solid Tumor.

CFTX-1554 is under clinical development by Eli Lilly and Co and currently in Phase I for Peripheral Neuropathic Pain.

S-95024 is under clinical development by Les Laboratoires Servier and currently in Phase II for Non-Small Cell Lung Cancer.

Bevacizumab biosimilar is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Cervical Cancer.

HPG-1860 is under clinical development by Hepagene Therapeutics Shanghai and currently in Phase I for Inflammatory Bowel Disease.

Icerguastat is under clinical development by InFlectis BioScience and currently in Phase I for Charcot-Marie-Tooth Disease Type I B.

Onvapegleukin alfa is under clinical development by Ascendis Pharma and currently in Phase II for Human Papillomavirus (HPV) Associated Cancer.

Long-Acting Injectable Program is under clinical development by Intra-Cellular Therapies and currently in Phase I for Schizoaffective Disorder.